Wei Zongyi, Zhou Yuxin, Wang Rongjie, Wang Jin, Chen Zhenhua
Jiangxi Province Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science and Technology Normal University, Nanchang 330013, China.
Pharmaceutics. 2022 Nov 22;14(12):2561. doi: 10.3390/pharmaceutics14122561.
Undesirable side effects and multidrug tolerance are the main holdbacks to the treatment of cancer in conventional chemotherapy. Fortunately, targeted drug delivery can improve the enrichment of drugs at the target site and reduce toxicity to normal tissues and cells. A targeted drug delivery system is usually composed of a nanocarrier and a targeting component. The targeting component is called a "ligand". Aptamers have high target affinity and specificity, which are identified as attractive and promising ligands. Therefore, aptamers have potential application in the development of smart targeting systems. For instance, aptamers are able to efficiently recognize tumor markers such as nucleolin, mucin, and epidermal growth factor receptor (EGFR). Besides, aptamers can also identify glycoproteins on the surface of tumor cells. Thus, the aptamer-mediated targeted drug delivery system has received extensive attention in the application of cancer therapy. This article reviews the application of aptamers as smart ligands for targeted drug delivery in cancer therapy. Special interest is focused on aptamers as smart ligands, aptamer-conjugated nanocarriers, aptamer targeting strategy for tumor microenvironment (TME), and aptamers that are specified to crucial cancer biomarkers for targeted drug delivery.
不良副作用和多药耐药性是传统化疗治疗癌症的主要阻碍。幸运的是,靶向给药可以提高药物在靶部位的富集,并降低对正常组织和细胞的毒性。靶向给药系统通常由纳米载体和靶向组件组成。靶向组件被称为“配体”。适体具有高靶向亲和力和特异性,被认为是有吸引力和前景的配体。因此,适体在智能靶向系统的开发中具有潜在应用。例如,适体能够有效识别核仁素、粘蛋白和表皮生长因子受体(EGFR)等肿瘤标志物。此外,适体还可以识别肿瘤细胞表面的糖蛋白。因此,适体介导的靶向给药系统在癌症治疗应用中受到了广泛关注。本文综述了适体作为智能配体在癌症治疗靶向给药中的应用。特别关注的是作为智能配体的适体、适体偶联纳米载体、针对肿瘤微环境(TME)的适体靶向策略以及用于靶向给药的特定关键癌症生物标志物的适体。
Pharmaceutics. 2022-11-22
Int J Nanomedicine. 2020-2-17
J Control Release. 2013-6-15
Drug Discov Today. 2023-5
Int J Pharm. 2022-5-25
Int J Mol Sci. 2015-10-9
Crit Rev Biochem Mol Biol. 2011-9-28
Expert Opin Drug Deliv. 2015-3
Nanoscale Adv. 2025-8-8
Viruses. 2025-2-1
In Vitro Model. 2023-7-13
Pharmaceutics. 2024-6-27
Mol Ther Nucleic Acids. 2024-4-24
Pharmaceutics. 2024-4-14
ACS Appl Mater Interfaces. 2022-9-28
Biosensors (Basel). 2022-7-29
Polymers (Basel). 2022-8-8